Lenalidomide and Chronic Lymphocytic Leukemia
Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance. This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2013 |
|---|---|
| Enthalten in: |
BioMed Research International - (2013) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ana Pilar González-Rodríguez [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2013/932010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ00229687X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ00229687X | ||
| 003 | DE-627 | ||
| 005 | 20230309165925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2013/932010 |2 doi | |
| 035 | |a (DE-627)DOAJ00229687X | ||
| 035 | |a (DE-599)DOAJ169044ae43d14a64b9dd468f0ff4db09 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Ana Pilar González-Rodríguez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lenalidomide and Chronic Lymphocytic Leukemia |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Lenalidomide is an oral immunomodulatory drug used in multiple myeloma and myelodysplastic syndrome and most recently it has shown to be effective in the treatment of various lymphoproliferative disorders such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. The mechanism of action of lenalidomide varies depending on the pathology, and in the case of CLL, it appears to primarily act by restoring the damaged mechanisms of tumour immunosurveillance. This review discusses the potential mechanism of action and efficacy of lenalidomide, alone or in combination, in treatment of CLL and its toxic effects such as tumor lysis syndrome (TLS) and tumor flare reaction (TFR), that make its management different from other hematologic malignancies. | ||
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Angel R. Payer |e verfasserin |4 aut | |
| 700 | 0 | |a Andrea Acebes-Huerta |e verfasserin |4 aut | |
| 700 | 0 | |a Leticia Huergo-Zapico |e verfasserin |4 aut | |
| 700 | 0 | |a Monica Villa-Alvarez |e verfasserin |4 aut | |
| 700 | 0 | |a Esther Gonzalez-García |e verfasserin |4 aut | |
| 700 | 0 | |a Segundo Gonzalez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BioMed Research International |d Hindawi Limited, 2013 |g (2013) |w (DE-627)DOAJ000078204 |x 23146141 |7 nnns |
| 773 | 1 | 8 | |g year:2013 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2013/932010 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/169044ae43d14a64b9dd468f0ff4db09 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2013/932010 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2314-6133 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2314-6141 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2013 | ||